Nebula Genomics secures major international B2B deal – Additional significant B2B deals in final stages Ahead of schedule, Pharmaloz Manufacturing accelerates capacity expansion – set for ...

ProPhase Labs Inc. has announced the formation of a Clinical Science Advisory Board to support the commercialization of its BE-Smart™ molecular test for esophageal disease, aimed at early ...

ProPhase Labs announces BE-Smart's validation for esophageal disease diagnostics, achieving over 95% success in detecting critical biomarkers. ProPhase Labs Inc. announced the successful ...

Positive Points ProPhase Labs Inc (NASDAQ:PRPH) has significantly reduced overhead by selling PMI and shutting down their lab, which is expected to improve financial efficiency. The company has ...

GARDEN CITY, NY, March 27, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs Inc. (NASDAQ: PRPH), (the "Company” or "ProPhase”), a next generation biotech, genomics and consumer products company, today announced ...

ProPhase will also present to shareholders today, May 20, 2025, at 10am EST during the live Virtual Non-Deal Roadshow Series hosted by Renmark Financial Communications Inc.

ProPhase Labs, Inc. (NASDAQ:PRPH) Q1 2025 Earnings Call Transcript May 20, 2025 ProPhase Labs, Inc. beats earnings expectations. Reported EPS is $-0.14, expectations were $-0.18. Noella Alexander ...

Ted Karkus, CEO of ProPhase Labs, will present to shareholders today, March 31, 2025, at 11:00 a.m. EST during the live Virtual Non-Deal Roadshow Series. The details are available below.